|
Progress in medical therapy in aplastic anemia: why it took so long? |
Feb 2024 |
International Journal of Hematology |
Aplastic Anemia |
|
Progress in the Management of Pregnancy with Paroxysmal Nocturnal Hemoglobinuria: A Review |
Jan 2024 |
Journal of Women's Health |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Quality of life after immune suppressive therapy in aplastic anemia |
Apr 2024 |
Annals of Hematology |
Aplastic Anemia |
|
Raising the bar for lower-risk myelodysplastic syndromes |
Jun 2023 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Raising the bar for lower-risk myelodysplastic syndromes |
Apr 2023 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Randomized trials with checkpoint inhibitors in acute myeloid leukaemia and myelodysplastic syndromes: What have we learned so far and where are we heading? |
Dec 2020 |
Best practice & research. Clinical haematology |
Myelodysplastic Syndromes (MDS) |
|
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria |
Sep 2019 |
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis |
Jun 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes |
Apr 2024 |
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
|
Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria |
May 2021 |
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
